Raltitrexed
Raltitrexed is an antineoplastic agent primarily used in the treatment of certain cancers. This medication belongs to a class of drugs known as antifolates, which interfere with cell growth.

Key Takeaways
- Raltitrexed is an antifolate chemotherapy drug used in oncology.
- It primarily targets thymidylate synthase, an enzyme crucial for DNA synthesis in cancer cells.
- The drug is administered intravenously, often for metastatic colorectal cancer.
- Common side effects include gastrointestinal issues, myelosuppression, and fatigue.
- Careful monitoring and management of potential drug interactions are essential during treatment.
What is Raltitrexed?
Raltitrexed is a chemotherapy drug classified as an antifolate antineoplastic agent. It is designed to disrupt the growth and spread of cancer cells by interfering with specific biochemical pathways essential for cell division. Developed as a thymidylate synthase inhibitor, it offers a targeted approach to cancer treatment, particularly in cases where other therapies may be less effective or contraindicated. Its mechanism of action distinguishes it from other chemotherapy agents, making it a valuable option in specific clinical settings.
Raltitrexed Uses, Mechanism of Action, and Dosage
The primary application for raltitrexed uses and side effects (with a focus on uses here) is in the treatment of advanced or metastatic colorectal cancer. It has been evaluated for use as a single agent or in combination with other chemotherapy drugs, depending on the patient’s specific condition and treatment history. The effectiveness of Raltitrexed stems from its unique raltitrexed mechanism of action.
Raltitrexed works by inhibiting thymidylate synthase (TS), an enzyme critical for the synthesis of thymidylate, which is a precursor required for DNA replication and repair. By blocking TS, Raltitrexed effectively depletes the cellular supply of thymidylate, leading to DNA damage and ultimately inducing apoptosis (programmed cell death) in rapidly dividing cancer cells. This selective interference with DNA synthesis makes it an effective cytotoxic agent.
Dosage for Raltitrexed is typically administered intravenously (IV) over a short period, often every three weeks. The precise dose depends on factors such as the patient’s body surface area, renal function, and overall health status. Close monitoring by healthcare professionals is crucial to optimize treatment efficacy and manage potential toxicities.
Common clinical indications for Raltitrexed include:
- Treatment of metastatic colorectal cancer, particularly in patients who cannot tolerate fluoropyrimidine-based regimens.
- As a component in certain combination chemotherapy protocols.
Potential Side Effects and Drug Interactions of Raltitrexed
As with many chemotherapy agents, Raltitrexed can cause a range of side effects. Understanding raltitrexed uses and side effects is crucial for patient management. Common side effects often include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and mucositis. Myelosuppression, characterized by a decrease in blood cell counts (anemia, leukopenia, thrombocytopenia), is also a significant concern, increasing the risk of infection and bleeding. Fatigue, skin reactions, and elevated liver enzymes may also occur. Less common but serious side effects can include severe allergic reactions or interstitial pneumonitis.
Effective management of side effects often involves supportive care, including antiemetics for nausea, antidiarrheals, and growth factors to mitigate myelosuppression. Regular monitoring of blood counts and liver function is essential throughout the treatment course to detect and address adverse reactions promptly.
Regarding raltitrexed drug information, it is important to consider potential interactions with other medications. Drugs that affect renal function or are also metabolized by similar pathways could alter Raltitrexed’s efficacy or toxicity. For instance, concomitant use with folic acid or folinic acid supplements may reduce its effectiveness, as these can interfere with the drug’s antifolate mechanism. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid adverse interactions and ensure safe treatment.



















